[HTML][HTML] Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients–30 months follow‐up
TL Larsen, H Garresori, J Brekke, T Enden… - Journal of Thrombosis …, 2022 - Elsevier
Background There are no data on the effect of low‐dose anticoagulation as secondary
prophylaxis for venous thromboembolism (VTE) in cancer patients. We assessed the efficacy …
prophylaxis for venous thromboembolism (VTE) in cancer patients. We assessed the efficacy …
Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients–30 months follow‐up
TL Larsen, H Garresori, J Brekke… - … of Thrombosis and …, 2022 - Wiley Online Library
Background There are no data on the effect of low‐dose anticoagulation as secondary
prophylaxis for venous thromboembolism (VTE) in cancer patients. We assessed the efficacy …
prophylaxis for venous thromboembolism (VTE) in cancer patients. We assessed the efficacy …
[PDF][PDF] Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients–30 months follow-up
TL Larsen, H Garresori, J Brekke, T Enden, H Frøen… - 2022 - pfizerpro.lt
Background: There are no data on the effect of low-dose anticoagulation as secondary
prophylaxis for venous thromboembolism (VTE) in cancer patients. We assessed the efficacy …
prophylaxis for venous thromboembolism (VTE) in cancer patients. We assessed the efficacy …
Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients–30 months follow‐up
TL Larsen, H Garresori, J Brekke, T Enden… - Journal of Thrombosis …, 2022 - jthjournal.org
Background There are no data on the effect of low‐dose anticoagulation as secondary
prophylaxis for venous thromboembolism (VTE) in cancer patients. We assessed the efficacy …
prophylaxis for venous thromboembolism (VTE) in cancer patients. We assessed the efficacy …
Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients-30 months follow-up.
TL Larsen, H Garresori, J Brekke, T Enden… - … of Thrombosis and …, 2022 - europepmc.org
Background There are no data on the effect of low-dose anticoagulation as secondary
prophylaxis for venous thromboembolism (VTE) in cancer patients. We assessed the efficacy …
prophylaxis for venous thromboembolism (VTE) in cancer patients. We assessed the efficacy …
Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients-30 months follow-up
TL Larsen, H Garresori, J Brekke… - … of thrombosis and …, 2022 - pubmed.ncbi.nlm.nih.gov
Background There are no data on the effect of low-dose anticoagulation as secondary
prophylaxis for venous thromboembolism (VTE) in cancer patients. We assessed the efficacy …
prophylaxis for venous thromboembolism (VTE) in cancer patients. We assessed the efficacy …
Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients–30 months follow-up
TL Larsen, H Garresori, J Brekke, TR Enden… - Journal of Thrombosis …, 2022 - duo.uio.no
Background There are no data on the effect of low-dose anticoagulation as secondary
prophylaxis for venous thromboembolism (VTE) in cancer patients. We assessed the efficacy …
prophylaxis for venous thromboembolism (VTE) in cancer patients. We assessed the efficacy …
Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients–30 months follow-up
TL Larsen, H Garresori, J Brekke, TR Enden, H Frøen… - 2022 - ntnuopen.ntnu.no
Background-There are no data on the effect of low‐dose anticoagulation as secondary
prophylaxis for venous thromboembolism (VTE) in cancer patients. We assessed the efficacy …
prophylaxis for venous thromboembolism (VTE) in cancer patients. We assessed the efficacy …